Daily-Practice Treatment of Acute Exacerbations of Chronic Bronchitis with Moxifloxacin in a Large Cohort in Germany
- First Online:
- 13 Downloads
To monitor the efficacy and safety of moxifloxacin in respiratory tract infections (RTIs) focussing on acute exacerbations of chronic bronchitis (AECB).
Patients with RTIs could be enrolled in this open-label, prospective, non-controlled post-marketing surveillance study from October 2001 until Junev 2002 unless moxifloxacin was contraindicated. At the initial visit, data were recorded on patient demographics, diagnosis and clinical symptoms. Two follow-up examinations could be performed to determine cure or improvement based on clinical symptoms, and to record adverse events. Clinical symptoms including fever, cough and purulent sputum were assessed individually. Efficacy, tolerability and patient acceptance were assessed globally at the final visit.
Of 9036 enrolled patients, 4328 had AECB, most of whom were treated with moxifloxacin at a daily dose of 400mg. Mean ± SD time to clinical improvement was 3.4 ± 1.5 days, and mean ± SD time to clinical cure was 6.6 ± 2.4 days. Cure rates were 39.4% at day 5 and 94.3% at day 10. By day 6, the proportion of patients with severe cough decreased from 85.4% at the initial visit to 6.9%, and those with severe dyspnoea from 22.5% to 1.2%. Purulent sputum was absent within 4 days in the majority of cases. Physicians rated efficacy, tolerability and patient acceptance as ‘very good’ or ‘good’ in approximately 95% of patients. There were 59 adverse events in 44 (1.0%) patients, most frequently gastrointestinal and nervous system disorders.
This study further confirms that AECB patients treated with moxifloxacin benefit from more rapid symptom relief and that this therapy option is well accepted in general practice.
- 15.Reynolds HY. Chronic bronchitis and acute infectious exacerbations. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 5th ed. New York: Churchill Livingstone, 2000: 706–710Google Scholar
- 18.Morrissey I, Colclough A, Viljoen L, et al. The comparative in vitro activity of moxifloxacin against respiratory tract pathogens isolated during 2003 from LIBRA Targeted Surveillance. Clin Microbiol Infect 2004; 10 Suppl. 3: 117–8Google Scholar
- 20.Jones ME, Sahm DF, Martin N, et al. Prevalence of gyrA, gyrB, parC and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the 1997–1998 respiratory season. Antimicrob Agents Chemother 2000; 44: 462–6PubMedCrossRefGoogle Scholar
- 21.Jones ME, Karlowsky JA, Blosser-Middleton R, et al. Apparent plateau in beta-lactamase production among clinical isolates of Haemophilus influenzae and Moraxella catarrhalis in the United States: results from the LIBRA Surveillance initiative. Int J Antimicrob Agents 2002; 19: 119–23PubMedCrossRefGoogle Scholar
- 31.DeAbate CA, Mathew CP, Warner JH, et al. The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbations of chronic bronchitis. Respir Med 2000; l94: 1029–37Google Scholar
- 37.Lode H, Kubin R, Reiter C. Safety update of oral moxifloxacin: a review of worldwide post-marketing surveillance [abstract]. Clin Microbiol Infect 2002; 8 Suppl. 1: 323–4Google Scholar